Advertisement
U.S. markets closed

Medigene AG (MDG1.DE)

XETRA - XETRA Delayed Price. Currency in EUR
1.7400+0.1200 (+7.41%)
At close: 05:38PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.6200
Open1.6950
Bid1.6100 x 57900
Ask1.7200 x 150900
Day's Range1.6050 - 1.8000
52 Week Range1.3500 - 2.2700
Volume62,713
Avg. Volume9,786
Market Cap42.739M
Beta (5Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-1.1900
Earnings DateMar 27, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MDG1.DE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Medigene AG to report full year 2023 financial results on March 28, 2024

      Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2023, on Thursday, March 28, 2024. Following the release of the full year 2023 earnings results and annual report on Medigene’s website, the Company will host a conference call that same day at 3 pm CET / 10 am

    • GlobeNewswire

      Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting

      Planegg/Martinsried, March 6, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer Research Annual Meeting (AACR) 2024 taking place from April 5-10, 2024 in San Diego, USA as well as an oral presentation at the ELRIG-Forum 2024 to be held in Darmstadt, Germany on March 7, 2024. Poster presentati

    • GlobeNewswire

      Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo

      Planegg/Martinsried, March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the Japan Patent Office protecting its inducible Medigene T cell receptor (iM-TCR), a control mechanism to regulate efficacy and safety of its T cell receptor engineered T cell (TCR-T) therapies. “We are delighted with the receipt